Supersapiens

Supersapiens

Growth Stage

Glucose: The Cornerstone of Metabolic Health

Glucose: The Cornerstone of Metabolic Health

Overview

Raised to Date: Raised: $0

Total Commitments ($USD)

Platform

Republic

Start Date

12/04/2023

Close Date

03/03/2024

Min. Goal
$250,000
Max. Goal
$3,765,000
Min. Investment

$250

Security Type

Convertible Note

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$120,000,000

Discount

20%

Rolling Commitments ($USD)

Status
Not Funded
Reporting Date

03/01/2024

Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise

$0

Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

Low

Location

ATLANTA, Georgia

Business Type

High Growth

Supersapiens, with a valuation of $120 million, is raising funds on Republic. The company has developed a real-time biometrics platform to monitor and optimize human health and performance. Supersapiens’ platform offers real-time glucose monitoring and provides metabolic insights, assistance, and education for athletes. The platform has over 15,000 users and generated $2 million in revenue in 2022. Phil Southerland, Jay Robbins, and Fitzalan Crowe founded Supersapiens in February 2019. The current crowdfunding campaign has a minimum target of $250,000 and a maximum target of $3.8 million. The campaign proceeds will be used for technology and product development, sales and marketing, science and research and development, infrastructure, and general working capital.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$1,961,323

$1,832,611

COGS

$2,019,568

$2,709,094

Tax

$392

$1,517

 

 

Net Income

$-11,458,731

$-14,197,534

Summary Balance Sheet

FY 2022 FY 2021

Cash

$211,211

$571,660

Accounts Receivable

$21,366

$14,874

Total Assets

$2,639,240

$5,125,416

Short-Term Debt

$4,799,773

$2,151,423

Long-Term Debt

$11,586,212

$14,294,462

Total Liabilities

$16,385,985

$16,445,885

Financials as of: 12/04/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Supersapiens 03/02/2024 Republic $120,000,000 $0 Convertible Note Not Funded RegCF
Supersapiens 04/27/2023 Republic $85,000,000 $1,235,000 Convertible Note Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Supersapiens on Republic 2023
Platform: Republic
Security Type: Convertible Note
Valuation: $120,000,000

Follow company

Follow Supersapiens on Republic 2023

Buy Supersapiens's Deal Report

Warning: according to the close date for this deal, Supersapiens may no longer be accepting investments.

Supersapiens Deal Report

Get KingsCrowd’s comprehensive report on Supersapiens including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Supersapiens is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Supersapiens deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge